Continuing Medical Education Posttest
The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:
Top Antivir Med. December 2014/January 2015, Volume 22, Issue 5
- CME Credit Available: 2.0 AMA PRA Category 1 Credits™
- Release Date: January 19, 2015
- Expiration Date: January 19, 2016
To complete the activity, read the articles, successfully complete the posttest, submit the evaluation, and complete and submit the CME claim form.
On completion of this activity, the learner will be able to:
- Describe advances in antiretroviral therapy, HIV and metabolism, HIV/hepatitis C virus coinfection, and tuberculosis research presented at the 2014 International AIDS Conference.
- Describe typical presentations of syphilis, gonorrhea, and other sexually transmitted infections in the context of HIV infection, as well as screening practices and treatment methods for each.
- List recommendations for HIV prevention in clinical care settings, including those for HIV testing, antiretroviral therapy, preexposure and postexposure prophylaxis, risk-reduction measures, and engagement of HIV-infected patients in the HIV care continuum.
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians on the evolving challenges of managing HIV disease. This activity examines selected highlights from the 2014 International AIDS Conference in Melbourne, Australia; sexually transmitted diseases, particularly syphilis and gonorrhea, in the context of HIV infection; and HIV prevention in the clinical care setting.
This enduring material is designed for physicians and other health care practitioners who are experienced in the principles of complex chemotherapy (eg, antiretroviral therapy) and are actively treating or will be treating patients with HIV infection.
This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is offered from January 19, 2015, to January 19, 2016. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.
Disclosure of Financial Interests
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing medical education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Dr Volberding has served on scientific advisory boards for Bristol-Myers Squibb and Gilead Sciences, Inc. (12/22/14)
Dr Marrazzo has served as a consultant or advisor to AstraZeneca. (1/5/15)
Dr del Rio has no relevant financial affiliations to disclose. (12/26/14)
Dr Richman has been a consultant to Bristol-Myers Squibb, Chimerix, Gen-Probe, Inc, Gilead Sciences, Inc, Sirenas, Prism, and Monogram Biosciences, Inc. He owns stock from Chimerix. (7/17/14)
Dr Benson has no relevant financial affiliations to disclose. Disclosure information for her spouse, Robert T. Schooley, MD, is indicated below. (4/28/14)
Dr Schooley has received research support from Boehringer Ingelheim Pharmaceuticals, Inc, and Bristol-Myers Squibb. He has served as a consultant or advisor to or on a data monitoring committee for Bristol-Myers Squibb, GlobeImmune, Gilead Sciences, Inc, and Monogram Biosciences. He serves as a consultant to and has stock options from CytoDyn, and he owns stock from GlobeImmune. (1/14/15)
Dr Hirsch has no relevant financial affiliations to disclose. (10/31/14)
Ms Jacobsen has no relevant financial affiliations to disclose. (1/20/15)
The nonstaff members of the Topics in Antiviral Medicine™ Editorial Board participate in a volunteer capacity. They are not compensated for their role in overseeing the program.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:
Independent educational grants for the 2014 Improving the Management of HIV Disease CME program:
Gilead Sciences, Inc
Merck & Co, Inc
Salix Pharmaceuticals, Inc
Drug and Product Disclaimer
This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the IAS–USA.
If you have any questions about this activity, please contact the IAS–USA:
Mail: 425 California Street, Suite 1450, San Francisco, CA 94104-2120
By clicking "Begin," I acknowledge that I have read these instructions and understand them.
You must log in to take the activity.